Table 2. Serum Lipids and Apolipoproteins of the Participants in the ATBI, CE, LI, and Control Groups.
| ATBI (n = 52) | CE (n = 15) | LI (n = 25) | CONT (n = 21) | |
|---|---|---|---|---|
| Serum lipids | ||||
| TC, mg/dL | 178.4 ± 43.0 | 195.3 ± 35.8 | 195.6 ± 55.4 | 205.6 ± 29.7 |
| LDL-C, mg/dL | 106.8 ± 29.7 | 113.1 ± 27.1 | 121.0 ± 39.6 | 118.6 ± 32.2 |
| MDA-LDL, U/L | 103.8 ± 44.7 | 130.7 ± 48.9 | 100.8 ± 45.1 | 92.4 ± 18.5 |
| HDL-C, mg/dL | 54.6 ± 12.5 | 57.5 ± 19.4 | 66.2 ± 17.1 | 67.0 ± 23.7 |
| TG, mg/dL | 147.9 ± 84.2 | 161.7 ± 107.9 | 128.5 ± 82.2 | 142.5 ± 62.9 |
| RLP-C, mg/dL | 6.7 ± 7.0 | 10.0 ± 7.5 | 7.1 ± 5.1 | 6.8 ± 3.2 |
| Lp(a), mg/dL | 18.0 ± 21.7 | 21.3 ± 33.5 | 29.1 ± 44.2 | 14.8 ± 12.0 |
| Apolipoproteins | ||||
| ApoA1, mg/dL | 128.6 ± 19.6a | 131.9 ± 25.3 | 139.2 ± 17.1 | 149.3 ± 21.5 |
| ApoA2, mg/dL | 27.9 ± 4.9 | 30.2 ± 5.5 | 27.4 ± 4.3 | 30.1 ± 4.7 |
| ApoB, mg/dL | 79.1 ± 17.3 | 89.2 ± 16.6 | 80.6 ± 29.1 | 76.5 ± 9.2 |
| ApoC2, mg/dL | 4.5 ± 1.7 | 5.9 ± 2.3 | 4.7 ± 2.4 | 4.9 ± 1.7 |
| ApoC3, mg/dL | 9.9 ± 4.3 | 11.2 ± 3.5 | 9.9 ± 3.4 | 10.7 ± 3.0 |
| ApoE, mg/dL | 3.1 ± 1.2 | 3.7 ± 1.2 | 3.4 ± 1.3 | 3.4 ± 0.8 |
| HbA1c, % | 6.6 ± 1.5 | 6.0 ± 1.8 | 6.4 ± 1.3 | 6.1 ± 0.7 |
aP < 0.05, vs. CONT. ATBI: atherothrombotic infarction; CE: cardioembolic infarction; LI: lacuna infraction; CONT: control; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; MDA-LDL: malondialdehyde-modified low-density lipoprotein; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; RLP-C: remnant lipoprotein cholesterol; Lp(a): lipoprotein(a); ApoA1: apolipoprotein A1; ApoA2: apolipoprotein A2; ApoB: apolipoprotein B; ApoC1: apolipoprotein C1; ApoC2: apolipoprotein C2; ApoE: apolipoprotein E; HbA1c: hemoglobin A1c.